To our knowledge, this is the first pilot study that has explored the safety, pharmacokinetic, and efficacy profile of first‐generation EGFR‐TKIs (gefitinib of 250 mg) in combination with an oral VEGFR‐TKIs (apatinib of 500 or 250 mg) for EGFR‐mutant advanced non‐squamous NSCLC. Here, KDR is linked to non-small cell lung carcinoma.